William Townsend

8PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 17, 2026
Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

|Jun 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

|Mar 27, 2026
Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Andrea Kuhnl, Amy A Kirkwood, Michael Northend

|Aug 14, 2025
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Alex F Herrera, Stephen M Ansell, Pier Luigi Zinzani

|Oct 17, 2024
Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England.

Christopher P Fox, William Townsend, John G Gribben

|Aug 30, 2024
Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study.

Simon Renders, Maud Ngoya, Herve Finel

Pageof 2

Frequent Collaborators

3 joint publications

Christopher P Fox

2 joint publications

Nicolás Martinez-Calle

2 joint publications

Andrew J Davies

1 joint publications

Wojciech Jurczak